Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2016)

Soleno Therapeutics (SLNO) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $13.0 as the latest value for Q4 2016.

  • Quarterly Preferred Stock Liabilities rose 160.0% to $13.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $13.0 through Dec 2016, up 160.0% year-over-year, with the annual reading at $13.0 for FY2016, 160.0% up from the prior year.
  • Preferred Stock Liabilities for Q4 2016 was $13.0 at Soleno Therapeutics, up from $5.0 in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $15.4 million in Q4 2013, with the low at $5.0 in Q4 2015.
  • Average Preferred Stock Liabilities over 4 years is $7.7 million, with a median of $7.7 million recorded in 2014.
  • Peak annual rise in Preferred Stock Liabilities hit 160.0% in 2016, while the deepest fall reached 160.0% in 2016.
  • Over 4 years, Preferred Stock Liabilities stood at $15.4 million in 2013, then fell by 0.0% to $15.4 million in 2014, then plummeted by 100.0% to $5.0 in 2015, then surged by 160.0% to $13.0 in 2016.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $13.0, $5.0, and $15.4 million for Q4 2016, Q4 2015, and Q3 2014 respectively.